261 related articles for article (PubMed ID: 34706496)
1. Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
Allard P; Alhaj N; Lobitz S; Cario H; Jarisch A; Grosse R; Oevermann L; Hakimeh D; Tagliaferri L; Kohne E; Kopp-Schneider A; Kulozik AE; Kunz JB
Haematologica; 2022 Jul; 107(7):1577-1588. PubMed ID: 34706496
[TBL] [Abstract][Full Text] [Related]
2. The role of BCL11A and HMIP-2 polymorphisms on endogenous and hydroxyurea induced levels of fetal hemoglobin in sickle cell anemia patients from southern Brazil.
Friedrisch JR; Sheehan V; Flanagan JM; Baldan A; Summarell CC; Bittar CM; Friedrisch BK; Wilke II; Ribeiro CB; Daudt LE; da Rocha Silla LM
Blood Cells Mol Dis; 2016 Nov; 62():32-37. PubMed ID: 27838552
[TBL] [Abstract][Full Text] [Related]
3. Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia.
Sales RR; Belisário AR; Faria G; Mendes F; Luizon MR; Viana MB
Ann Hematol; 2020 Jul; 99(7):1453-1463. PubMed ID: 32447424
[TBL] [Abstract][Full Text] [Related]
4. Association between BCL11A, HSB1L-MYB, and XmnI γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patients.
El-Ghamrawy M; Yassa ME; Tousson AMS; El-Hady MA; Mikhaeil E; Mohamed NB; Khorshied MM
Ann Hematol; 2020 Oct; 99(10):2279-2288. PubMed ID: 32772141
[TBL] [Abstract][Full Text] [Related]
5. Fetal hemoglobin-boosting haplotypes of BCL11A gene and HBS1L-MYB intergenic region in the prediction of clinical and hematological outcomes in a cohort of children with sickle cell anemia.
Sales RR; Nogueira BL; Belisário AR; Faria G; Mendes F; Viana MB; Luizon MR
J Hum Genet; 2022 Dec; 67(12):701-709. PubMed ID: 36167770
[TBL] [Abstract][Full Text] [Related]
6. The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.
Adekile A
Med Princ Pract; 2021; 30(3):201-211. PubMed ID: 32892201
[TBL] [Abstract][Full Text] [Related]
7. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.
Lettre G; Sankaran VG; Bezerra MA; Araújo AS; Uda M; Sanna S; Cao A; Schlessinger D; Costa FF; Hirschhorn JN; Orkin SH
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11869-74. PubMed ID: 18667698
[TBL] [Abstract][Full Text] [Related]
8. Fetal hemoglobin in sickle cell anemia: molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans.
Akinsheye I; Solovieff N; Ngo D; Malek A; Sebastiani P; Steinberg MH; Chui DH
Am J Hematol; 2012 Feb; 87(2):217-9. PubMed ID: 22139998
[TBL] [Abstract][Full Text] [Related]
9.
Gardner K; Fulford T; Silver N; Rooks H; Angelis N; Allman M; Nkya S; Makani J; Howard J; Kesse-Adu R; Rees DC; Stuart-Smith S; Yeghen T; Awogbade M; Sangeda RZ; Mgaya J; Patel H; Newhouse S; Menzel S; Thein SL
Blood Adv; 2018 Feb; 2(3):235-239. PubMed ID: 29437638
[TBL] [Abstract][Full Text] [Related]
10. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
11. The association of HBG2, BCL11A, and HMIP polymorphisms with fetal hemoglobin and clinical phenotype in Iraqi Kurds with sickle cell disease.
Al-Allawi N; Qadir SMA; Puehringer H; Chui DHK; Farrell JJ; Oberkanins C
Int J Lab Hematol; 2019 Feb; 41(1):87-93. PubMed ID: 30216683
[TBL] [Abstract][Full Text] [Related]
12. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness.
Zhu X; Hu T; Ho MH; Wang Y; Yu M; Patel N; Pi W; Choi JH; Xu H; Ganapathy V; Kutlar F; Kutlar A; Tuan D
Haematologica; 2017 Dec; 102(12):1995-2004. PubMed ID: 28971909
[TBL] [Abstract][Full Text] [Related]
14. DNA polymorphisms at BCL11A, HBS1L-MYB and Xmn1-HBG2 site loci associated with fetal hemoglobin levels in sickle cell anemia patients from Northern Brazil.
Cardoso GL; Diniz IG; Silva AN; Cunha DA; Silva Junior JS; Uchôa CT; Santos SE; Trindade SM; Cardoso Mdo S; Guerreiro JF
Blood Cells Mol Dis; 2014 Dec; 53(4):176-9. PubMed ID: 25084696
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
[TBL] [Abstract][Full Text] [Related]
16. Fetal hemoglobin regulating genetic variants identified in homozygous (HbSS) and heterozygous (HbSA) subjects from South Mexico.
Rizo-de la Torre LC; Borrayo-López FJ; Perea-Díaz FJ; Aquino E; Venegas M; Hernández-Carbajal C; Espinoza-Mata LL; Ibarra-Cortés B
J Trop Pediatr; 2022 Aug; 68(5):. PubMed ID: 36130307
[TBL] [Abstract][Full Text] [Related]
17. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
18. Combined and differential effects of alpha-thalassemia and HbF-quantitative trait loci in Senegalese hydroxyurea-free children with sickle cell anemia.
Gueye Tall F; Martin C; Ndour EHM; Renoux C; Ly ID; Connes P; Gueye PM; Diallo RN; Diagne I; Diop PA; Cissé A; Lopez Sall P; Joly P
Pediatr Blood Cancer; 2019 Oct; 66(10):e27934. PubMed ID: 31322815
[TBL] [Abstract][Full Text] [Related]
19. Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.
Bernaudin F; Arnaud C; Kamdem A; Hau I; Lelong F; Epaud R; Pondarré C; Pissard S
Blood Adv; 2018 Mar; 2(6):626-637. PubMed ID: 29555644
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
